Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: An opportunity to consider non-communicable diseases in resource-limited settings.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
04
2020
accepted:
29
01
2021
entrez:
16
2
2021
pubmed:
17
2
2021
medline:
5
8
2021
Statut:
epublish
Résumé
With the introduction of effective antiretroviral therapy (ART), people living with HIV (PLWH) are surviving longer and are at risk for developing metabolic abnormalities that contribute to cardiovascular disease (CVD). In Sub-Saharan Africa (SSA), there is a paucity of epidemiological data on lipid profiles among young adults receiving ART. This study aimed to estimate the prevalence of low high-density lipoprotein cholesterol (HDL-c), a cardioprotective lipid class, and whether it differed by age among adults on ART in Livingstone, Zambia. From April to December 2019, we conducted a cross-sectional study of 597 PLWH [n = 58 aged 18-24 years (young adults); n = 539 aged ≥25 years (adults)] on ART for ≥6 months. Data collected included demographic and lifestyle information, anthropometrics, viral load (VL), CD4 count, blood pressure, lipid profiles and fasting/random blood glucose. Clinical measures were defined as: low HDL-c [<1.0 mmol/L for men, <1.3 for women], increased waist circumference (WC) [≥94 cm for men, ≥80 cm for women], high triglycerides (TG) [≥1.7 mmol/l], and virological failure (VF) [VL ≥1000 copies/μl]. We used logistic regression to examine the association between age and low HDL-c after adjusting for multiple variables. Among the young adults, 60% (35/58) were women, median (25th, 75th percentile) age 21 years (18, 23), and median time on ART 116 months (60, 144). Among adults, 63% (342/539) were women, median age 46 years (40, 53) and median time on ART 108 months (60, 144). Young adults had a lower CD4 count compared to adults (median, 492 vs. 568 cells/μL, p = 0.010) and higher prevalence of VF (29% vs. 17%, p = 0.016). In young adults, prevalence of low HDL-c was significantly higher than in adults (63 vs. 38%, p<0.001). A high proportion of young adults (75%) and adults (58%) with low HDL-c were on dolutegravir (DTG)-based ART regimens. After adjusting for sex, duration on ART, WC, body mass index, ART regimen, VF, CD4 count, low density lipoprotein cholesterol, blood pressure and smoking, young adults were significantly more likely than adults to have low HDL-c (odds ratio 2.93; 95% confidence interval 1.46-5.86). Low HDL-c is highly prevalent among young adult with HIV in SSA independent of other risk factors for metabolic derangements. Lipid abnormalities among young PLWH may contribute to the early development of cardiovascular diseases in this population. This highlights the need to consider low HDL-c in the quest to reduce CVD risk among young adults on ART in SSA.
Sections du résumé
BACKGROUND
With the introduction of effective antiretroviral therapy (ART), people living with HIV (PLWH) are surviving longer and are at risk for developing metabolic abnormalities that contribute to cardiovascular disease (CVD). In Sub-Saharan Africa (SSA), there is a paucity of epidemiological data on lipid profiles among young adults receiving ART. This study aimed to estimate the prevalence of low high-density lipoprotein cholesterol (HDL-c), a cardioprotective lipid class, and whether it differed by age among adults on ART in Livingstone, Zambia.
METHODS
From April to December 2019, we conducted a cross-sectional study of 597 PLWH [n = 58 aged 18-24 years (young adults); n = 539 aged ≥25 years (adults)] on ART for ≥6 months. Data collected included demographic and lifestyle information, anthropometrics, viral load (VL), CD4 count, blood pressure, lipid profiles and fasting/random blood glucose. Clinical measures were defined as: low HDL-c [<1.0 mmol/L for men, <1.3 for women], increased waist circumference (WC) [≥94 cm for men, ≥80 cm for women], high triglycerides (TG) [≥1.7 mmol/l], and virological failure (VF) [VL ≥1000 copies/μl]. We used logistic regression to examine the association between age and low HDL-c after adjusting for multiple variables.
RESULTS
Among the young adults, 60% (35/58) were women, median (25th, 75th percentile) age 21 years (18, 23), and median time on ART 116 months (60, 144). Among adults, 63% (342/539) were women, median age 46 years (40, 53) and median time on ART 108 months (60, 144). Young adults had a lower CD4 count compared to adults (median, 492 vs. 568 cells/μL, p = 0.010) and higher prevalence of VF (29% vs. 17%, p = 0.016). In young adults, prevalence of low HDL-c was significantly higher than in adults (63 vs. 38%, p<0.001). A high proportion of young adults (75%) and adults (58%) with low HDL-c were on dolutegravir (DTG)-based ART regimens. After adjusting for sex, duration on ART, WC, body mass index, ART regimen, VF, CD4 count, low density lipoprotein cholesterol, blood pressure and smoking, young adults were significantly more likely than adults to have low HDL-c (odds ratio 2.93; 95% confidence interval 1.46-5.86).
CONCLUSION
Low HDL-c is highly prevalent among young adult with HIV in SSA independent of other risk factors for metabolic derangements. Lipid abnormalities among young PLWH may contribute to the early development of cardiovascular diseases in this population. This highlights the need to consider low HDL-c in the quest to reduce CVD risk among young adults on ART in SSA.
Identifiants
pubmed: 33592027
doi: 10.1371/journal.pone.0247004
pii: PONE-D-20-09386
pmc: PMC7886128
doi:
Substances chimiques
Cholesterol, LDL
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247004Subventions
Organisme : FIC NIH HHS
ID : D43 TW009744
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Acquir Immune Defic Syndr. 2007 May 1;45(1):34-42
pubmed: 17460470
J R Soc Interface. 2018 Apr;15(141):
pubmed: 29618526
J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):159-63
pubmed: 26307211
Lipids Health Dis. 2010 Dec 30;9:147
pubmed: 21190590
Curr Atheroscler Rep. 2011 Oct;13(5):405-12
pubmed: 21744164
Circulation. 2018 Sep 11;138(11):1100-1112
pubmed: 29967196
AIDS. 2010 Mar 13;24(5):697-706
pubmed: 20177360
J Lipid Res. 1994 May;35(5):871-82
pubmed: 8071609
Arteriosclerosis. 1988 Nov-Dec;8(6):737-41
pubmed: 3196218
J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):304-11
pubmed: 18398971
Diabetes Metab Res Rev. 2018 Jan;34(1):
pubmed: 28886616
Clin Infect Dis. 2013 Jun;56(12):1820-8
pubmed: 23449270
Can J Cardiol. 1988 Jul;4 Suppl A:5A-10A
pubmed: 3179802
BMC Res Notes. 2016 Mar 05;9:145
pubmed: 26945987
Braz J Infect Dis. 2011 Mar-Apr;15(2):151-5
pubmed: 21503402
Climacteric. 2019 Dec;22(6):610-616
pubmed: 31364889
Open Biochem J. 2012;6:78-93
pubmed: 22888373
Lancet. 2014 Sep 13;384(9947):1005-70
pubmed: 25059949
Biochem Res Int. 2016;2016:3204818
pubmed: 27051532
Postgrad Med. 2000 Apr;107(4):141-6
pubmed: 10778417
Clin Infect Dis. 2010 May 15;50(10):1387-96
pubmed: 20380565
PLoS One. 2016 Mar 17;11(3):e0151911
pubmed: 26986065
World J Virol. 2015 May 12;4(2):56-77
pubmed: 25964872
J Frailty Aging. 2019;8(2):88-92
pubmed: 30997922
Infect Drug Resist. 2019 May 23;12:1385-1391
pubmed: 31213857
Mol Med. 2020 Jan 15;26(1):7
pubmed: 31941463
J Health Econ. 2020 Mar;70:102300
pubmed: 32014825
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Cardiovasc Res. 2002 Feb 15;53(3):550-7
pubmed: 11861025
Open Cardiovasc Med J. 2011;5:49-63
pubmed: 21643501
Lipids Health Dis. 2017 Jun 9;16(1):110
pubmed: 28599673
J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):164-71
pubmed: 26514630
Braz J Infect Dis. 2010 Nov-Dec;14(6):575-88
pubmed: 21340298
Ann Clin Biochem. 2007 May;44(Pt 3):232-63
pubmed: 17456293
N Engl J Med. 1998 Jun 4;338(23):1650-6
pubmed: 9614255
J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350
pubmed: 30423393
Niger J Clin Pract. 2015 Sep-Oct;18(5):626-32
pubmed: 26096241
Indian J Med Res. 2017 May;145(5):641-650
pubmed: 28948955
PLoS Pathog. 2010 Jul 01;6:e1000981
pubmed: 20617179
Clin Infect Dis. 2006 Sep 1;43(5):645-53
pubmed: 16886161
AIDS. 2018 Jul 1;32 Suppl 1:S5-S20
pubmed: 29952786
PLoS One. 2017 Jun 5;12(6):e0177440
pubmed: 28582393
AIDS Patient Care STDS. 2008 Jul;22(7):569-75
pubmed: 18479224
J Virol. 2011 Oct;85(20):10834-50
pubmed: 21849441
Retrovirology. 2018 Dec 14;15(1):77
pubmed: 30547820
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
PLoS One. 2018 May 21;13(5):e0197728
pubmed: 29782548
N Engl J Med. 2007 Sep 27;357(13):1301-10
pubmed: 17898099
J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70
pubmed: 20700060
BMC Res Notes. 2014 Jun 21;7:380
pubmed: 24950924
BMC Public Health. 2014 Sep 02;14:904
pubmed: 25183300
Circulation. 2002 Mar 5;105(9):1135-43
pubmed: 11877368
Neuroimage. 2020 Mar;208:116459
pubmed: 31837471
PLoS One. 2015 May 14;10(5):e0126166
pubmed: 25974077
Clin Drug Investig. 2015 Mar;35(3):211-9
pubmed: 25637061
Exp Mol Pathol. 2020 Oct;116:104493
pubmed: 32659237
Atherosclerosis. 2006 Jan;184(1):72-7
pubmed: 15935358